C4 Therapeutics
CCCC
102 hedge funds and large institutions have $78.2M invested in C4 Therapeutics in 2025 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 32 increasing their positions, 32 reducing their positions, and 39 closing their positions.
693% more call options, than puts
Call options by funds: $111K | Put options by funds: $14K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 32
11% less funds holding
Funds holding: 114 → 102 (-12)
13.28% less ownership
Funds ownership: 90.3% → 77.02% (-13%)
24% less capital invested
Capital invested by funds: $103M → $78.2M (-$24.4M)
31% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.51M |
| 2 |
Renaissance Technologies
New York
|
+$1.28M |
| 3 |
Morgan Stanley
New York
|
+$1.03M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$1.02M |
| 5 |
Jane Street
New York
|
+$698K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.03M |
| 2 |
SC
Samlyn Capital
New York
|
-$4.82M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.96M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$1.57M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.41M |
CCCC Hedge Fund Activity: Q2 2025 in Review
102 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q2 2025, worth a combined $78.2M — down 24% from $103M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of CCCC and 27 opened new positions — a net loss of 12 holders — while 32 trimmed existing stakes and 32 added.
The largest buyer was Millennium Management, adding an estimated $1.51M. The largest seller was BlackRock, cutting an estimated $5.03M.
- 102 institutional investors held C4 Therapeutics (CCCC) as of Q2 2025, down from 114 in Q1 2025.
- Funds reported $78.2M of C4 Therapeutics stock for Q2 2025, down 24% quarter-over-quarter.
- 27 funds opened new C4 Therapeutics positions in Q2 2025 and 39 closed out, a net change of -12 holders.
- The largest C4 Therapeutics buyer in Q2 2025 was Millennium Management, an estimated $1.51M added.
- The largest C4 Therapeutics seller in Q2 2025 was BlackRock, an estimated $5.03M sold.
Based on aggregated 13F filings for Q2 2025.